Clinical trial
Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism
NCT07852637
Study timeline
Study start (estimated)2026-11-01Date precision: day
Registry last updated2026-10-01
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Venous Thromboembolismunresolved
Active Cancerunresolved
Interventions
edoxabanDRUG · verified · RxNorm: edoxaban
ApixabanDRUG · verified · RxNorm: apixaban
Sponsors & collaborators
Samsung Medical Centerlead sponsor
Seoul National University Hospitalcollaborator
National Cancer Center, Koreacollaborator
Seoul St. Mary's Hospitalcollaborator
Dong-A University Hospitalcollaborator
Chonnam National University Hospitalcollaborator
Korea University Anam Hospitalcollaborator
Inje University Ilsan Paik Hospitalcollaborator
Konkuk University Hospitalcollaborator
Chung-Ang University Gwangmyeong Hospitalcollaborator
Chonbuk National University Hospitalcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07852637 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.